Surrozen, Inc. [Rocket]

Date Filed

Type

Description

08/17/2021

Director compensation was amended/approved

Docs:

"Certificate of Incorporation of Surrozen, Inc",
"Bylaws of Surrozen, Inc",
"Certificate of Corporate Domestication of Consonance-HFW Acquisition Corp",
"Investor Rights Agreement, by and among Surrozen, Inc., Consonance Life Sciences, and certain other investors",
"SURROZEN, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 14, 2021 APPROVED BY THE STOCKHOLDERS: AUGUST 10, 2021 1. GENERAL. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. Available Awards. The Plan provides for the grant of the following Awards: Incentive Stock Options; Nonstatutory Stock Options; SARs; Restricted Stock Awards; RSU Awards; Performance Awards; and Other Awards. Adoption Date; Effective Date. The Pl...",
"SURROZEN, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 14, 2021 APPROVED BY THE STOCKHOLDERS: AUGUST 10, 2021 1. GENERAL; PURPOSE. The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends the 423 Component to qualify as an Employee Stock Purchase Plan. The provi...",
"Form of Indemnification Agreement",
"Securities and Exchange Commission 100 F Street, N.E.",
"List of Subsidiaries",
"Unaudited Condensed Interim Financial Statements and Related Notes of Legacy Surrozen, Inc. as of June 30, 2021 and 2020"

04/15/2021

8-K

Director compensation was amended/approved

Docs:

"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 15, 2021 Consonance-HFW Acquisition Corp. Cayman Islands 001-39635 98-15556622 1 Palmer Square, Suite 305 Princeton, NJ 08540 921-2333 Registrant's telephone number, including area code Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ...",
"BUSINESS COMBINATION AGREEMENT BY AND AMONG CONSONANCE-HFW ACQUISITION CORP., PERSEVERANCE MERGER SUB INC., AND, SURROZEN, INC. DATED AS OF APRIL 15, 2021",
"Sponsor Letter Agreement, by and among Consonance-HFW Acquisition Corp., Consonance Life Sciences, Donald J. Santel, Christopher Haqq, Jennifer Jarrett and Surrozen, Inc.",
"Form of Subscription Agreement",
"Form of Surrozen Transaction Support Agreement",
"Form of CHFW Transaction Support Agreement",
"Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration",
"Investor Presentation",
"Investor Script",
"Surrozen Business and Risk Factor Disclosures"